New combo therapy shows promise for rare blood cancer

NCT ID NCT05379166

Ongoing Disease control Sponsor: Uma Borate Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial is testing whether combining venetoclax and azacitidine can help people with therapy-related myelodysplastic syndrome (t-MDS), a blood cancer that develops after prior cancer treatment. The study will enroll 33 adults and measure how many achieve complete remission. The goal is to find a more effective treatment for this difficult-to-treat condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: venetoclax and azacitidine
What this could lead to: If successful, this combination could offer a new treatment option for therapy-related myelodysplastic syndrome, potentially leading to higher remission rates.
What could go wrong: This is a small, early-phase trial with only 33 participants, so results may not apply to everyone. Side effects from the drugs are possible, and the treatment may not work for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SECONDARY MYELODYSPLASTIC SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SECONDARY MYELODYSPLASTIC SYNDROME THERAPY-RELATED MYELODYSPLASTIC SYNDROME

Contacts and locations

Locations

Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
Oregon Health & Science University

Portland, Oregon, 97239, United States
University of Texas Southwestern Medical Center

Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.